Skye Bioscience announced that it presented new data in a poster titled “Development and screening of a novel library of synthetic endocannabinoid agonists and inhibitors to advance a potential therapy to treat dry eye disease and chronic ocular pain” on May 9th at the ARVO 2024 Annual Meeting. Key highlights include: presented biological ECS screening program focused on pathways relevant to dry eye disease, or DED, and chronic ocular pain; three synthetic cannabinoid-based compounds relevant to DED and chronic ocular pain have been identified for further pharmaceutical development; a unique screening approach has the potential to provide a new class of therapeutics with novel mechanisms of action for the treatment of diverse ocular pathologies. A rigorous in vitro screening platform based on modulation of pathways relevant to cannabinoid biology in the context of ocular pathologies was designed to interrogate a library of 98 synthetic cannabinoid-based molecules for their potential to treat ocular diseases.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKYE:
- Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
- Skye Bioscience management to meet with Oppenheimer
- Skye Bioscience to Present at Upcoming Investment Conferences
- Skye Bioscience management to meet with Morgan Stanley
- Skye Bioscience initiated with an Outperform at Oppenheimer